Ipamorelin
NeuroprotectionResearchers tracking Ipamorelin for cognitive and neurological endpoints describe a restorative rather than stimulant phenotype. The compound supports recovery from neurological injury, modulates neuroinflammatory tone, and stabilises monoamine and HPA-axis signalling. Dosing at 200-300 mcg 1-3x daily subq via subq delivers exposure consistent with the ~2 hr half-life and the typical 8-12 week cycle pattern used in nootropic-research protocols.
Key Takeaways
Cognitive lens: Ipamorelin acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Highly selective GHSR1a agonist. Neuro dose: 200-300 mcg 1-3x daily subq via subq; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
Ipamorelin's neurological relevance starts with how the compound reaches the central nervous system. Highly selective GHSR1a agonist. Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell. Direct blood-brain barrier transport is rarely the dominant route for peptide compounds; vagal-afferent gut-brain signalling and effects on cerebral vasculature where the barrier is locally compromised typically produce the CNS phenotype. The detail follows.
Receptor pharmacology and selectivity profile
Ipamorelin's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Highly selective GHSR1a agonist. Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing Ipamorelin with peptides engaging the same primary receptor produces competition rather than synergy.
Central nervous system access
Ipamorelin reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq route(s) and ~2 hr half-life set the timeline for CNS exposure. Highly selective GHSR1a agonist. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Cerebral perfusion and the structural cognitive substrate
Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. Ipamorelin, with its Highly selective GHSR1a agonist Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The ~2 hr pharmacokinetic profile supports this restorative rather than stimulant phenotype.
Where Ipamorelin is used for cognitive recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Post-TBI Recovery is one of the more-reported subjective benefits of Ipamorelin across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For focus & executive function, Ipamorelin is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where Ipamorelin is used for hpa axis modulation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 200-300 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 120-300 mcg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 200-300 mcg | 1-3x daily SubQ |
| Maintenance phase | SubQ | 140-300 mcg | Ongoing with periodic pauses |
Dose timing for Ipamorelin is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
Ipamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- Ipamorelin + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Ipamorelin's mechanism in cognitive / neurological protocols.
- Ipamorelin + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with Ipamorelin's mechanism in cognitive / neurological protocols.
- Ipamorelin + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Ipamorelin's mechanism in cognitive / neurological protocols.
- Ipamorelin + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Ipamorelin's mechanism in cognitive / neurological protocols.
Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional.
Lens-specific safety considerations for cognitive / neurological use of Ipamorelin: Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
Can Ipamorelin be stacked with other nootropics?
Best route for cognitive applications — injection or oral?
Is Ipamorelin a true nootropic?
Cognitive side effects to watch for?
What is the evidence base for Ipamorelin?
What does Ipamorelin stack well with?
Start a Ipamorelin Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified Ipamorelin and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 712 Da
- Sequence length
- 5 aa
- Half-life
- ~2 hr
- WADA
- Banned (S2)
- FDA
- Unapproved
- Research
- Phase II in GH deficiency; off-label use widespread
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Ipamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for Ipamorelin
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised